Revenue in 1H26 was £0.6m (1H25: £1.0m), predominantly from the DRIVE35 PRIMED grant-funded programme. This programme commenced in August 2025 and will continue to grow throughout 2H26. Grant funding continues to provide important resources during the commercialisation phase of Ilika’s two main product lines, Stereax small scale batteries for medical and industrial devices, and the larger scale Goliath cells for use in EVs and consumer electronics. Current grant funding is nearing completion and ....
